Sign up to our newsletter and updates.
Intraday Hi-Lo:
52-Week Hi-Lo:
Related Companies:
Curated Stories & News
Cannabis Science, Inc. (CBIS) Issues 2019 Guidance Report
Cannabis Science Issues 2019 Guidance Report; Under SEC Sanctions the Compa
Cannabis Science, Inc. (CBIS) Enters Transition Stage as Trading of the Company’s Shares is Halted
Cannabis Science Enters Transition Stage as Trading of the Company’s Shar
Cannabis Science, Inc. (CBIS) Partners With CDN Firm NHS Industries
Cannabis Science Partners With CDN Firm NHS Industries to Launch the CBIS&h
Mr. Raymond C. Dabney Prepares Cannabis Science, Inc. (CBIS) for the Next Level
Mr. Raymond C. Dabney Prepares Cannabis Science for the Next Level With&hel
Cannabis Science, Inc. (CBIS) Set to Participate in the Premier Event Focused on High-Impact Global Collaborations
Cannabis Science Set to Participate in the Premier Event Focused on High-Im
Cannabis Science, Inc. (CBIS) Releases Clinical Drug-Development Pipeline
Cannabis Science Releases Clinical Drug-Development Pipeline as it Transiti
Cannabis Science, Inc. (CBIS) Negotiates Licensing and Marketing Deals in Canada and the USA to Develop and Sell CBN Products
Independent Valuation of U.S. Patent Number 9,763,991 for Cannabinol (CBN)
Cannabis Science, Inc. (CBIS) Receives Tremendous Response for CEO’s Personal Shareholder Loyalty Gift
Cannabis Science Receives Tremendous Response for CEO’s Personal Sharehol
$CBIS Highlights Additional Attendees at the Washington DC, African Union
Cannabis Science Highlights Additional Attendees at the Washington DC, Afri